Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

161. Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence

Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Postmenopausal Breast Cancer Incidence 22927520 2012 10 01 2012 12 10 2016 10 19 1527-7755 30 28 2012 Oct 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. 3468-77 The associations between use of aspirin, other (...) documented 4,734 cases of incident invasive breast cancer. Compared with nonuse of aspirin, multivariable RRs of regular aspirin use (≥ two tablets per week) for more than 20 years were 0.91 for overall breast cancer (95% CI, 0.81 to 1.01; P(trend) = 0.16), 0.90 for estrogen receptor (ER) -positive progesterone receptor (PR) -positive breast cancer (95% CI, 0.77 to 1.06; P(trend) = 0.17), and 0.91 for ER-negative PR-negative breast cancer (95% CI, 0.68 to 1.22; P(trend) = 0.97). Results did not vary

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

162. Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm.

Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. ACP Journal Club: warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation (...) manager Format Create File 1 selected item: 22910961 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Aug 21;157(4):JC2-7. doi: 10.7326/0003-4819-157-4-201208210-02007. ACP Journal Club: warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. 1 , . 1 Duke University School of Medicine, Durham

Annals of Internal Medicine2012

163. Review: Daily aspirin reduces short-term risk for cancer and cancer mortality.

Review: Daily aspirin reduces short-term risk for cancer and cancer mortality. ACP Journal Club. Review: daily aspirin reduces short-term risk for cancer and cancer mortality. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 22801694 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jul 17;157(2):JC2-2, JC2-3. doi: 10.7326/0003-4819-157-2-201207170-02002. ACP Journal Club. Review: daily aspirin reduces short-term risk for cancer and cancer mortality. . Comment on [Lancet. 2012] PMID: 22801694 DOI: Publication type Full Text Sources

Annals of Internal Medicine2012

164. Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding.

Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding. ACP Journal Club. Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 (...) selected item: 22711104 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Jun 19;156(12):JC6-3. doi: 10.7326/0003-4819-156-12-201206190-02003. ACP Journal Club. Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding. 1 . 1 University of Virginia, Charlottesville, Virginia, USA. Comment on [Arch Intern Med

Annals of Internal Medicine2012

165. Association of aspirin use with major bleeding in patients with and without diabetes.

Association of aspirin use with major bleeding in patients with and without diabetes. CONTEXT: The benefit of aspirin for the primary prevention of cardiovascular events is relatively small for individuals with and without diabetes. This benefit could easily be offset by the risk of hemorrhage. OBJECTIVE: To determine the incidence of major gastrointestinal and intracranial bleeding episodes in individuals with and without diabetes taking aspirin. DESIGN, SETTING, AND PARTICIPANTS: A population (...) -based cohort study, using administrative data from 4.1 million citizens in 12 local health authorities in Puglia, Italy. Individuals with new prescriptions for low-dose aspirin (≤300 mg) were identified during the index period from January 1, 2003, to December 31, 2008, and were propensity-matched on a 1-to-1 basis with individuals who did not take aspirin during this period. MAIN OUTCOME MEASURES: Hospitalizations for major gastrointestinal bleeding or cerebral hemorrhage occurring after

JAMA2012

166. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z CRD summary The review concluded that, as well as reducing the long-term risk (...) of some cancers, aspirin may also prevent distant cancer metastasis. Despite a lack of reporting of some aspects of the review and the restriction to UK trials, the authors' conclusions appear likely to be reliable. Authors' objectives To examine the effect of daily aspirin on the risk of cancer metastasis. Searching The authors used search results from two previous studies. PubMed and EMBASE (2002 to May 2011) and Cochrane Database of Systematic Reviews were searched. Search terms were reported

DARE.2012

167. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits (...) in 51 randomised controlled trials Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW CRD summary This meta-analysis used mainly individual patient data on people treated with low-dose daily aspirin for primary prevention of vascular events. The authors found a short-term reduction in cancer incidence and mortality and a decrease in major extracranial bleeds with extended use of aspirin. Despite being based on a subset of included

DARE.2012

168. Esomeprazole Alone Compared with Esomeprazole Plus Aspirin for the Treatment of Aspirin-Related Peptic Ulcers

Esomeprazole Alone Compared with Esomeprazole Plus Aspirin for the Treatment of Aspirin-Related Peptic Ulcers 22508148 2012 07 05 2012 10 24 2015 11 19 1572-0241 107 7 2012 Jul The American journal of gastroenterology Am. J. Gastroenterol. Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. 1022-9 10.1038/ajg.2012.87 Aspirin-related peptic ulcers are a common disorder. However, whether or not aspirin should be continued during treatment (...) for aspirin-related ulcers remains unclear. To compare esomeprazole alone with esomeprazole plus aspirin in the treatment of aspirin-related peptic ulcers and to investigate the independent factors associated with the failure of ulcer healing. From January 2008 to July 2011, patients with aspirin-related peptic ulcers were randomized to receive esomeprazole (40 mg per day) alone or esomeprazole (40 mg per day) plus aspirin (100 mg per day) for 8 weeks. The subjects with Helicobacter pylori infection were

EvidenceUpdates2012

169. Effect of aspirin on mortality in the primary prevention of cardiovascular disease

Effect of aspirin on mortality in the primary prevention of cardiovascular disease Effect of aspirin on mortality in the primary prevention of cardiovascular disease Effect of aspirin on mortality in the primary prevention of cardiovascular disease Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J CRD summary This review concluded that aspirin prevented deaths, myocardial infarction and ischaemic stroke and increased hemorrhagic stroke and major bleeding when used in the primary (...) prevention of cardiovascular disease. This review was generally well conducted. However, the marginal effect detected in the pooled outcome particularly for all-cause mortality did not adequately support the authors' conclusions. Authors' objectives To assess the effect of aspirin on mortality in the primary prevention of cardiovascular disease. Searching MEDLINE, EMBASE, CINAHL and The Cochrane Library were searched from inception to May 2010. Search terms were reported. Reference lists of relevant

DARE.2012

171. Are we ready to recommend aspirin for the prevention of cancer?

Are we ready to recommend aspirin for the prevention of cancer? 22440945 2012 04 30 2012 05 14 2016 12 15 1474-547X 379 9826 2012 Apr 28 Lancet (London, England) Lancet Are we ready to recommend aspirin for cancer prevention? 1569-71 10.1016/S0140-6736(11)61654-1 Chan Andrew T AT Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. Cook Nancy R NR eng ClinicalTrials.gov NCT00501059 NCT01038583 R01 CA047988 CA NCI NIH HHS United States R01 CA137178 (...) CA NCI NIH HHS United States Comment Journal Article 2012 03 21 England Lancet 2985213R 0140-6736 0 Antineoplastic Agents 0 Platelet Aggregation Inhibitors R16CO5Y76E Aspirin AIM IM Ann Intern Med. 2009 Mar 17;150(6):396-404 19293072 Ann Intern Med. 1998 May 1;128(9):713-20 9556464 JAMA. 2005 Jul 6;294(1):47-55 15998890 Ann Intern Med. 2007 Mar 6;146(5):361-4 17339621 Arch Intern Med. 2007 Mar 26;167(6):562-72 17389287 J Natl Cancer Inst. 2009 Feb 18;101(4):256-66 19211452 Lancet. 2012 Apr 28;379

Lancet2012 Full Text: Link to full Text with Trip Pro

172. Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis: A Cohort Study.

Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis: A Cohort Study. BACKGROUND: Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are anti-inflammatory but have been linked in some studies to Crohn disease (CD) and ulcerative colitis (UC). OBJECTIVE: To assess the association between aspirin and NSAID use and incident CD and UC. DESIGN: Prospective cohort study. SETTING: Nurses' Health Study I. PATIENTS: 76,795 U.S. women who provided (...) biennially updated data about aspirin and NSAID use. MEASUREMENTS: Incident CD and UC between 1990 and 2008 (outcome) and NSAID and aspirin use (exposure). RESULTS: 123 incident cases of CD and 117 cases of UC occurred over 18 years and 1,295,317 person-years of follow-up. Compared with nonusers, women who used NSAIDs at least 15 days per month seemed to have increased risk for both CD (absolute difference in age-adjusted incidence, 6 cases per 100,000 person-years [95% CI, 0 to 13]; multivariate hazard

Annals of Internal Medicine2012 Full Text: Link to full Text with Trip Pro

173. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR CRD summary The review (...) concluded that aspirin reduced major cardiovascular events by about 10% but increased the incidence of major bleeding in individuals without clinical cardiovascular disease. A limited search, no quality assessment and insufficient reporting of review processes and control treatments mean that the authors' conclusions may not be reliable. Authors' objectives To evaluate the impact of aspirin treatment on major cardiovascular events and major bleeding in patients without clinical cardiovascular disease

DARE.2012

174. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer

Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Squires H, Tappenden P, Cooper K, Carroll C, Logan R, Hind D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of aspirin, celecoxib, or calcium for the prevention of colorectal cancer, with a screening programme, for the general population or those who had undergone colorectal polypectomy. Calcium chemoprevention was likely to be cost-effective after polypectomy, but the evidence was weak. Aspirin could be cost

NHS Economic Evaluation Database.2012

175. Cost-effectiveness comparison of breast cancer screening and vascular event primary prevention with aspirin in Wales

Cost-effectiveness comparison of breast cancer screening and vascular event primary prevention with aspirin in Wales Cost-effectiveness comparison of breast cancer screening and vascular event primary prevention with aspirin in Wales Cost-effectiveness comparison of breast cancer screening and vascular event primary prevention with aspirin in Wales Morgan G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of a health education programme plus aspirin for the primary prevention of vascular events in the general population aged 50 years or older, and compared this with the cost-effectiveness of breast cancer screening. The results supported the implementation of an education programme

NHS Economic Evaluation Database.2012

176. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials

Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK CRD summary The authors concluded that aspirin as primary prevention reduced risk of non-fatal (...) myocardial infarction, but not the risk of cardiovascular or cancer mortality; bleeding increased with aspirin. Further research was needed and guidelines should be reappraised. The authors’ conclusions reflect the evidence, but the limitations of the review should be borne in mind. Recommendations for further research seem appropriate. Authors' objectives To assess the effects of aspirin for the primary prevention of vascular and non-vascular outcomes. Searching PubMed and the Cochrane Library were searched from

DARE.2012

177. [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease]

[Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] Park BJ, Park YS, Choi NK, Lee YJ, Kim MS, Lee CW, Kang DY, Park SY, Park JE, Lee NR, Shin JY, Sung JM, Kim SM, Yang BR, Kim HM, Ahn HJ, Kim JY, Go YJ Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Park BJ, Park YS, Choi NK, Lee YJ, Kim MS, Lee CW, Kang DY, Park SY, Park JE, Lee NR, Shin JY, Sung JM, Kim SM, Yang BR, Kim HM, Ahn HJ, Kim JY, Go YJ. [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-11-002. 2012 Authors

Health Technology Assessment (HTA) Database.2012

178. Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events

Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Article Text Prognosis

Evidence-Based Medicine (Requires free registration)2012

179. Case control study: Use of non-aspirin NSAIDs during pregnancy may increase the risk of spontaneous abortion

Case control study: Use of non-aspirin NSAIDs during pregnancy may increase the risk of spontaneous abortion Use of non-aspirin NSAIDs during pregnancy may increase the risk of spontaneous abortion | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of non-aspirin NSAIDs during pregnancy may increase the risk of spontaneous abortion Article Text Midwifery Case control study Use of non-aspirin NSAIDs during pregnancy may increase the risk of spontaneous abortion Pamela Verma 1 , Christine A Clark 2

Evidence-Based Nursing (Requires free registration)2012

180. Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm

Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm Warfarin and aspirin did not diff... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation Short URL Annals of Internal Medicine ( 2012 ) Volume: 157 , Pages: JC2-7 ST - Warfarin and aspirin did not differ fo Available from or Find this paper at: Abstract QUESTION What are the relative efficacy and safety of warfarin and aspirin in patients (...) with heart failure who are in sinus rhythm? METHODS DESIGN Randomized controlled trial (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction WARCEF trial). ClinicalTrials.gov NCT00041938. ALLOCATION Concealed.+ BLINDING Blinded+ (patients, clinicians, data collectors, safety committee, and outcome assessors). FOLLOW-UP PERIOD =NON-BREAKING SPACE18 years of age (mean age 61 y, 80% men) who had a left ventricular ejection fraction (LVEF) NON-BREAKING SPACE4, medical conditions with high risk

Annals of Internal Medicine2012